2489390-15-8

2489390-15-8 structure

Name: KY-1044
Chemical Name: KY-1044
CAS Number: 2489390-15-8
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Cancer
Create Date: 2023-02-02 21:33:17
Modify Date: 2024-01-11 12:57:41
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOShigh cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response[1].

Name	KY-1044

Description	KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOShigh cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
In Vitro	KY-1044 (Alomfilimab; SAR 445256; 0-100ng/mL; 4 小时)导致表达 hICOS (5:1 效应子: 靶细胞比例) 的人类自然杀伤 (NK) 细胞诱导有效的 ADCC 介导的杀伤 (EC50=5.6 pmol/L)[1]。 KY-1044 显着诱导荧光素酶信号 (EC50 为 0.15 nmol/L)，对小鼠 ICOS (0.53 nmol/L)、大鼠 ICOS (0.48 nmol/L) 或食蟹猴 ICOS (0.22 nmol/L) 获得了相似的 EC50[1]。
In Vivo	KY-1044 (Alomfilimab; SAR 445256; 10 mg/kg; 腹腔注射; 每周两次; 持续 3 周) mIgG2a (效应物启用) 单一疗法可阻断淋巴瘤/骨髓瘤肿瘤模型中的肿瘤生长[1]。在同基因小鼠肿瘤模型中，KY-1044 耗尽 ICOShigh Treg 并增加瘤内 TEff:Treg 比率，导致 T 分泌 IFNγ 和 TNFα 增加 Eff 细胞[1]。 Animal Model: 8- to 10-week-old wild-type female Balb/C or C57BL/6J mice with A20 cells[1] Dosage: 200 μg (10 mg/kg) Administration: IP; twice a week for 3 weeks starting from 6 days following tumor cell implantation Result: Triggered an antitumor response, with more than 90% of the mice being free from measurable disease at the end of the study (day 42).
References	[1]. Richard C.A. Sainson, et al. An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression. Cancer Immunol Res. 2020 Dec;8(12):1568-1582.

No Any Chemical & Physical Properties

2489390-15-8	110816-78-9
2093407-25-9	1621673-53-7
1228280-29-2	468056-29-3
1223284-75-0	2093406-88-1
197894-84-1	92602-21-6
1158522-08-7	940364-43-2
2320379-12-0	134104-43-1
131615-57-1	2168843-95-4
6906-52-1	930439-75-1
1018584-77-4	1375289-11-4